阿替普酶与瑞替普酶治疗急性心肌梗死的疗效比较

目的：回顾性分析阿替普酶（rt-PA）和瑞替普酶（r-PA）治疗急性心肌梗死（AMI）患者的临床疗效。方法：观察使用阿替普酶全量加速给药或瑞替普酶静脉推注治疗的急性心肌梗死患者，分别统计两组胸痛至溶栓时间、再通率、出院前死亡率、治疗后并发症及再灌注心律失常发生率。结果：溶栓后，使用rt-PA的患者血管再通率84.6%，死亡率7.7%，出血率0%，再灌注心律失常发生率15.4%；使用r-PA的患者血管再通率90.9%，死亡率9.1%，出血率9.1%，再灌注心律失常发生率13.6%。结论：溶栓治疗急性心肌梗死rt-PA与r-PA两药比较疗效相当。

A Clinical Efficacy Analysis of rt-PA and r-PA in the Treatment of Acute Myocardial Infarction

Abstract Objective: A retrospective analysis of the clinical efficacy of rt-PA and r-PA in the treatment of acute myocardial infarction (AMI). Methods: In the treatment of acute myocardial infarction by accelerated full-dosage delivery of rt-Pa or intravenous injection of r-PA in patients with acute myocardial infarction, keep observation on them for chest pain, thrombolysis time, recanalization rate, mortality rate before their discharging, complications after the treatment and reperfusion arrhythmia incidence. Results: Of the patients who use rt-PA, after thrombolysis, vascular patency rate is 84.6%, mortality rate 7.7%, rate of bleeding 0%, and reperfusion arrhythmia incidence 15.4%; of those who use r-PA, vascular recanalization rate reaches 90.9%, mortality rate 9.1%, rate of bleeding 9.1%, and reperfusion arrhythmia incidence 13.6%.Conclusion: In the treatment of acute myocardial infarction by thrombolytic therapy, the efficacy of the two drugs, rt-PA and r-PA, is approximately equivalent.